LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 432

Search options

  1. Article ; Online: Reply: NAFLD vs. MASLD-There ain't no such thing as a free lunch.

    Rinella, Mary E / Lazarus, Jeffrey V / Newsome, Philip N

    Hepatology (Baltimore, Md.)

    2024  

    Language English
    Publishing date 2024-03-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604603-4
    ISSN 1527-3350 ; 0270-9139
    ISSN (online) 1527-3350
    ISSN 0270-9139
    DOI 10.1097/HEP.0000000000000854
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Book ; Thesis: The spread of HIV in Europe

    Lazarus, Jeffrey V.

    hidden epidemics and other barriers to universal access to prevention, treatment and care

    (Doctoral dissertation series; 2008,19 ; 2008,19)

    2008  

    Author's details Jeffrey V. Lazarus
    Series title Doctoral dissertation series; 2008,19 ; 2008,19
    Doctoral dissertation series
    Doctoral dissertation series; 2008,19
    Collection Doctoral dissertation series
    Doctoral dissertation series; 2008,19
    Language English ; Russian
    Size Getr. Zählung
    Publishing country Sweden
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Lund, Univ., Diss., 2008
    Note Zsfassung in russ. Sprache
    HBZ-ID HT016112816
    ISBN 978-91-85897-72-8 ; 91-85897-72-8
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  3. Article ; Online: A people-centred health system must be the foundation for person-centred care in the HIV response.

    Lazarus, Jeffrey V / Janamnuaysook, Rena / Caswell, Georgina

    Journal of the International AIDS Society

    2023  Volume 26 Suppl 1, Page(s) e26125

    MeSH term(s) Humans ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; HIV Infections/prevention & control ; Attitude of Health Personnel ; Surveys and Questionnaires ; Patient-Centered Care
    Language English
    Publishing date 2023-07-05
    Publishing country Switzerland
    Document type Editorial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2467110-1
    ISSN 1758-2652 ; 1758-2652
    ISSN (online) 1758-2652
    ISSN 1758-2652
    DOI 10.1002/jia2.26125
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Beyond a liver-gut focus: the evolution of gastroenterology and hepatology in challenging the obesity and steatotic liver disease paradigm.

    Brennan, Paul N / Zelber-Sagi, Shira / Allen, Alina M / Dillon, John F / Lazarus, Jeffrey V

    Gut

    2024  Volume 73, Issue 4, Page(s) 560–563

    MeSH term(s) Humans ; Gastroenterology ; Liver ; Fatty Liver/therapy ; Obesity/complications ; Obesity/therapy ; Non-alcoholic Fatty Liver Disease/complications ; Non-alcoholic Fatty Liver Disease/therapy
    Language English
    Publishing date 2024-03-07
    Publishing country England
    Document type Journal Article
    ZDB-ID 80128-8
    ISSN 1468-3288 ; 0017-5749
    ISSN (online) 1468-3288
    ISSN 0017-5749
    DOI 10.1136/gutjnl-2023-330771
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: It is time to expand the fatty liver disease community of practice.

    Lazarus, Jeffrey V / Kopka, Christopher J / Younossi, Zobair M / Allen, Alina M

    Hepatology (Baltimore, Md.)

    2023  Volume 78, Issue 5, Page(s) 1325–1328

    MeSH term(s) Humans ; Non-alcoholic Fatty Liver Disease/epidemiology ; Diabetes Mellitus, Type 2 ; Liver
    Language English
    Publishing date 2023-06-23
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604603-4
    ISSN 1527-3350 ; 0270-9139
    ISSN (online) 1527-3350
    ISSN 0270-9139
    DOI 10.1097/HEP.0000000000000411
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease".

    Newsome, Philip / Rinella, Mary E / Lazarus, Jeffrey V / Terrault, Norah

    Hepatology (Baltimore, Md.)

    2023  Volume 79, Issue 1, Page(s) E5–E6

    MeSH term(s) Humans ; Non-alcoholic Fatty Liver Disease
    Language English
    Publishing date 2023-08-30
    Publishing country United States
    Document type Letter
    ZDB-ID 604603-4
    ISSN 1527-3350 ; 0270-9139
    ISSN (online) 1527-3350
    ISSN 0270-9139
    DOI 10.1097/HEP.0000000000000587
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties.

    Allen, Alina M / Lazarus, Jeffrey V / Younossi, Zobair M

    Journal of hepatology

    2023  Volume 79, Issue 1, Page(s) 209–217

    Abstract: Left unaddressed, non-alcoholic fatty liver disease (NAFLD) will continue to have substantial health, economic and social implications. To address the challenge, a paradigm shift is needed in the way NAFLD is conceptualised. Concerted, collaborative ... ...

    Abstract Left unaddressed, non-alcoholic fatty liver disease (NAFLD) will continue to have substantial health, economic and social implications. To address the challenge, a paradigm shift is needed in the way NAFLD is conceptualised. Concerted, collaborative action across medical specialities, industry sectors and governments will be vital in tackling this public health threat. To drive this change, in this review, we present data on the current global healthcare and socioeconomic costs of NAFLD and highlight priority actions. The estimated healthcare costs of patients with NAFLD are nearly twice as high as their age-matched counterparts without the disease and are highest in those with advanced fibrosis and end-stage liver disease. NAFLD is accountable for the highest increase in DALYs (disability-adjusted life years) among all liver diseases globally. NAFLD and non-alcoholic steatohepatitis (NASH)-specific drug therapies are not yet available and there is considerable uncertainty regarding cost, optimal length of treatment, and their impact on liver-related outcomes and mortality. Among the currently available bariatric procedures, sleeve gastrectomy is reported to be the most cost-effective for NASH resolution. Gastric bypass remains very expensive, while data on bariatric endoscopy are limited. Lastly, we propose a global NAFLD/NASH investment framework to guide the development of achievable yet ambitious country-specific targets and strategic actions to optimise resource allocation and reduce the prevalence of NAFLD and NASH. Its focus on high-level inputs will be critical to enabling a political and financial environment that supports clinical-level implementation of NAFLD prevention, treatment and care efforts, across all settings.
    MeSH term(s) Humans ; Non-alcoholic Fatty Liver Disease/epidemiology ; Non-alcoholic Fatty Liver Disease/therapy ; Uncertainty ; Health Care Costs ; Socioeconomic Factors
    Language English
    Publishing date 2023-02-04
    Publishing country Netherlands
    Document type Journal Article ; Review ; Research Support, N.I.H., Extramural
    ZDB-ID 605953-3
    ISSN 1600-0641 ; 0168-8278
    ISSN (online) 1600-0641
    ISSN 0168-8278
    DOI 10.1016/j.jhep.2023.01.026
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Hepatocellular Carcinoma Prevention in the Era of Hepatitis C Elimination.

    Lazarus, Jeffrey V / Picchio, Camila A / Colombo, Massimo

    International journal of molecular sciences

    2023  Volume 24, Issue 18

    Abstract: The hepatitis C virus (HCV), a single-stranded RNA virus belonging to the Flaviviridae family, is a major cause of hepatocellular carcinoma (HCC) worldwide. Tumors caused by HCC have an increased mortality rate globally, which is more accentuated in ... ...

    Abstract The hepatitis C virus (HCV), a single-stranded RNA virus belonging to the Flaviviridae family, is a major cause of hepatocellular carcinoma (HCC) worldwide. Tumors caused by HCC have an increased mortality rate globally, which is more accentuated in Western countries. The carcinogenic potential of this virus is mediated through a wide range of mechanisms, spanning from the induction of chronic inflammation to oxidative stress and deregulation of cellular pathways by viral proteins. As the number of new infections continues unabated, HCC-related mortality should be prioritized through early detection, continued prevention of HCV transmission, and treatment of HCV with safe and efficacious direct antiviral agents (DAAs). People who inject drugs (PWID) are a significant reservoir of new HCV infections globally, and in order to eliminate hepatitis C as a global health threat, as set out by the World Health Organization, an integrated approach based on the optimization of care delivery and increased access to harm reduction and treatment for PWID is needed. Thanks to the development of safe and effective antiviral agents, eradication of the infection is now possible in almost all treated patients, leading to a significant reduction but not the elimination of the risk for HCC in cured patients. This is particularly relevant among aged populations who have cofactors of morbidity known to accelerate HCC progression, such as diabetes, obesity, and excessive alcohol consumption. Given the restless accumulation of individuals with cured HCV infection, the implementation of risk-stratified surveillance programs becomes impellent from a cost-effectiveness perspective, whereas the availability of a performant biomarker to predict HCC in cured patients remains an unmet clinical need.
    MeSH term(s) Humans ; Aged ; Carcinoma, Hepatocellular/epidemiology ; Carcinoma, Hepatocellular/etiology ; Carcinoma, Hepatocellular/prevention & control ; Hepacivirus ; Substance Abuse, Intravenous/complications ; Substance Abuse, Intravenous/drug therapy ; Liver Neoplasms/etiology ; Liver Neoplasms/prevention & control ; Liver Neoplasms/diagnosis ; Hepatitis C/complications ; Hepatitis C/drug therapy ; Hepatitis C/prevention & control ; Antiviral Agents/pharmacology ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/prevention & control
    Chemical Substances Antiviral Agents
    Language English
    Publishing date 2023-09-21
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms241814404
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: The path to successful hepatitis C elimination in Spain.

    Crespo, Javier / Cabezas, Joaquín / Calleja, José Luis / Buti, María / Lazarus, Jeffrey V

    Nature reviews. Gastroenterology & hepatology

    2023  Volume 20, Issue 11, Page(s) 689–690

    MeSH term(s) Humans ; Spain/epidemiology ; Hepatitis C/drug therapy ; Hepatitis C/epidemiology ; Hepatitis C/prevention & control ; Hepacivirus
    Language English
    Publishing date 2023-07-25
    Publishing country England
    Document type Journal Article
    ZDB-ID 2493722-8
    ISSN 1759-5053 ; 1759-5045
    ISSN (online) 1759-5053
    ISSN 1759-5045
    DOI 10.1038/s41575-023-00813-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Editor-in-Chief's welcome to

    Lazarus, Jeffrey V

    Hepatology, medicine and policy

    2016  Volume 1, Page(s) 1

    Abstract: Hepatology, Medicine and ... ...

    Abstract Hepatology, Medicine and Policy
    Language English
    Publishing date 2016-04-13
    Publishing country England
    Document type Editorial
    ISSN 2059-5166
    ISSN (online) 2059-5166
    DOI 10.1186/s41124-016-0005-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top